Ask AI
ProCE Banner Activity

Managing Relapsed/Refractory Diffuse Large B-Cell Lymphoma With ADCs: Answers to Frequently Asked Questions

Clinical Thought

Read this commentary with expert answers to frequently-asked questions regarding the use of antibody-drug conjugates (ADCs) as a therapeutic option(s) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma, including important factors to consider when selecting and sequencing ADCs and managing ADC-associated toxicities.

Released: October 30, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from ADC Therapeutics and Pfizer Inc.

ADC Therapeutics

Pfizer, Inc.

Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Foresight Diagnostics, Genentech, Gilead, Interius, Lilly, Miltenyi, Novartis, Roche, Seagen; researcher: Bristol Myers Squibb, Celgene, Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.

Michael R. Bishop, MD: consultant/advisor/speaker: CRISPR Therapeutics, Kite/Gilead, Novartis; researcher: Autolus, Ltd.